Jaguar Health Balance Sheet Health
Financial Health criteria checks 2/6
Jaguar Health has a total shareholder equity of $14.3M and total debt of $32.1M, which brings its debt-to-equity ratio to 224.5%. Its total assets and total liabilities are $55.4M and $41.1M respectively.
Key information
224.5%
Debt to equity ratio
US$32.11m
Debt
| Interest coverage ratio | n/a |
| Cash | US$11.67m |
| Equity | US$14.30m |
| Total liabilities | US$41.09m |
| Total assets | US$55.39m |
Recent financial health updates
Recent updates
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Mar 29
Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Jan 22Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
Jun 10Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
Jan 23Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment
Oct 17Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront
Aug 25Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule
Aug 19Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea
Aug 09Jaguar stock rises on license deal with SynWorld for Canalevia in China
Jun 29Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory
Mar 07Jaguar Health shares jumps 13% after pricing $15M direct offering
Jan 13Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients
Jan 11Jaguar Health leaps higher in new year
Jan 05Jaguar Health inks second Mytesi royalties agreement for $6M
Dec 23Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?
Dec 02
Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%
Nov 30Jaguar Health EPS misses by $0.10, misses on revenue
Nov 16Jaguar Health receives positive Nasdaq listing determination
Oct 29Financial Position Analysis
Short Term Liabilities: JAGX's short term assets ($33.7M) exceed its short term liabilities ($17.8M).
Long Term Liabilities: JAGX's short term assets ($33.7M) exceed its long term liabilities ($23.3M).
Debt to Equity History and Analysis
Debt Level: JAGX's net debt to equity ratio (142.9%) is considered high.
Reducing Debt: JAGX's debt to equity ratio has increased from 78.6% to 224.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: JAGX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: JAGX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.4% each year